On May 19, 2016 Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) reported an oral presentation on vosaroxin at the 21st Congress of the European Hematology Association (EHA) (Free EHA Whitepaper) to be held June 9-12, 2016 at the Bella Center in Copenhagen, Denmark (Press release, Sunesis, MAY 19, 2016, View Source;p=RssLanding&cat=news&id=2169705 [SID:1234512590]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details for the oral presentation are as follows:

Date & Time: Saturday, June 11, 2016, 5:00 p.m. to 5:15 p.m. Central European Time
Poster Title: Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (PTS) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Abstract Number: S505
Session Title: New Compounds in AML Treatment
Location: Hall A3

The full abstract can be viewed here.

The company will also publish data that will be on display as an E-poster:

Date & Time: Friday, June 10, 9:30 a.m. – Sunday, June 12, 11:00 a.m. Central European Time
Poster Title: Characterization of patients with relapsed or refractory AML in continued follow-up after treatment with vosaroxin/cytarabine vs placebo/cytarabine in the VALOR trial
Abstract Number: E930
Location: E-Poster Screens

The full abstract can be viewed here.